paroxetine has been researched along with fluvoxamine in 243 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.82) | 18.7374 |
| 1990's | 69 (28.40) | 18.2507 |
| 2000's | 106 (43.62) | 29.6817 |
| 2010's | 55 (22.63) | 24.3611 |
| 2020's | 11 (4.53) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojarski, AJ; Bugno, R; Duszyńska, B; Hogendorf, A; Hogendorf, AS; Kurczab, R; Lenda, T; Pietruś, W; Satała, G; Staroń, J; Wantuch, A; Warszycki, D | 1 |
| Crewe, HK; Haddock, RE; Lennard, MS; Tucker, GT; Woods, FR | 1 |
| Grimsley, SR; Jann, MW | 1 |
| DeVane, CL | 1 |
| Johnson, AM; Tulloch, IF | 1 |
| Goodman, WK; McDougle, CJ; Price, LH | 1 |
| Baldwin, D; Bullock, T; Montgomery, D; Montgomery, S | 1 |
| Fuller, RW | 1 |
| Asberg, M; Eriksson, B; Mårtensson, B; Träskman-Bendz, L; Wägner, A | 1 |
| Perez, J; Popoli, M; Racagni, G; Smeraldi, E; Vocaturo, C | 1 |
| Baumann, P; Rochat, B | 1 |
| Anelli, M; Caccia, S; Codegoni, AM; Fracasso, C; Garattini, S | 1 |
| Finley, PR | 1 |
| Hyttel, J; Sánchez, C | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL | 1 |
| Gray, AM; Rafieian-Kopaei, M; Sewell, RD; Spencer, PS | 1 |
| Rechlin, T | 1 |
| Feighner, JP | 1 |
| Brøsen, K | 1 |
| LaBranche, S | 1 |
| Joffe, RT; Levitt, AJ; Sokolov, ST; Young, LT | 1 |
| Bastani, AJ; Bastani, JB; Troester, MM | 1 |
| Newhouse, PA | 1 |
| Lazowick, AL; Levin, GM | 1 |
| Knowles, SR; Liu, BA; Mittmann, N; Shear, NH | 1 |
| Harvey, AT; Preskorn, SH | 2 |
| Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
| Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
| Egashira, T; Goto, S; Takayama, F; Wada, Y; Yamanaka, Y | 1 |
| Bell, CJ; Coupland, NJ; Potokar, JP | 1 |
| Leo, RJ | 1 |
| Harnett-Sheehan, K; Sheehan, DV | 1 |
| de Vet, HC; Hartmans, M; Honig, A; Menting, JE; Rozendaal, N; van Praag, HM; Verhey, FR | 1 |
| Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM | 1 |
| Preskorn, SH | 1 |
| Baumann, P; Eap, CB | 1 |
| MacKay, AV; Price, JS; Waller, PC; Wood, SM | 1 |
| Meier, E; Sánchez, C | 1 |
| Earley, B; Faherty, CJ; Leonard, BE | 1 |
| Black, KJ; Sheline, YI | 1 |
| Feiger, A; Kiev, A | 1 |
| Tielens, JA | 1 |
| Ahern, D; Ball, SE; Kao, J; Scatina, J | 1 |
| Di Mascio, M; Esposito, E | 1 |
| Bellodi, L; Bianchi, L; Mundo, E | 1 |
| Mitchell, S; Tracy, KA; Zajecka, J | 1 |
| Bousoño, M; Calcedo, A; Carrasco, JL; Ciudad, J; Daniel, E; De la Gandara, J; Derecho, J; Franco, M; Gomez, MJ; Izquierdo, JA; Ledesma, A; Llorca, G; Macias, JA; Martin, T; Montejo-González, AL; Perez, V; Sanchez, JM; Sanchez, S; Vicens, E | 1 |
| Richelson, E | 1 |
| Gorman, JM | 1 |
| Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J | 1 |
| Brochu, J; Cook, L; Feldkamp, M; Koren, G; Kulin, NA; Matsui, D; Ormond, K; Pastuszak, A; Rieder, M; Sage, SR; Schick-Boschetto, B; Spivey, G; Stein-Schechman, AK | 1 |
| Herrmann, N; Kalow, W; Naranjo, CA; Ozdemir, V; Reed, K; Sellers, EM; Shulman, RW | 1 |
| Grush, LR | 1 |
| Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
| Hengeveld, MW; Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Bourin, M; Redrobe, JP | 1 |
| Di Giovanni, G; Di Mascio, M; Di Matteo, V; Esposito, E; Prisco, S | 1 |
| Barbey, JT; Roose, SP | 1 |
| Gram, LF | 1 |
| Stahl, SM | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 1 |
| De Vry, J; Maurel, S; Schreiber, R | 1 |
| Carleborg, L; Hägg, S; Ohman, R; Spigset, O | 1 |
| Sheehan, DV | 1 |
| Bakker, A | 1 |
| Benmansour, S; Cecchi, M; Frazer, A; Gerhardt, GA; Gould, GG; Javors, MA; Morilak, DA | 1 |
| Baker, F; Day, A; Gath, DH; Mynors-Wallis, LM | 1 |
| Härtter, S; Hiemke, C | 1 |
| Gentilini, G; Lopez-Silva, S; Lucca, A; Soldarini, A | 1 |
| Freisleder, FJ; Mayer-Rosa, J; Rüth, U; Schlamp, D | 1 |
| Baier, D; Kohnen, R; Philipp, M; Tiller, JW | 1 |
| Bongiorno, F; Franchini, L; Rossini, D; Smeraldi, E; Spagnolo, C; Zanardi, R | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Consogno, E; Dorigo, C; Popoli, M; Racagni, G | 1 |
| Vallée, JP | 1 |
| Barnett, W; Fritzsche, M; Richter, P; Sattler, HD; von Turner, A | 1 |
| Fitzgerald, F; Glod, CA; Lynch, A | 1 |
| Dewa, CS; Goering, P; Hoch, JS | 1 |
| Gersh, T; Hobson, JA; Pace-Schott, EF; Salzman, C; Silvestri, R; Stickgold, R | 2 |
| Bergsholm, YK; Bøhler, E; Nordeng, H; Spigset, O | 1 |
| Altshuler, L; Brunhuber, MV; Fukuchi, A; Hendrick, V; Wertheimer, A; Widawski, M | 1 |
| Kuboki, T | 1 |
| Camarero, J; Colado, MI; Esteban, B; Green, AR; Peter, MJ; Sanchez, V | 1 |
| Bellodi, L; Cavallini, MC; Cavedini, P; Diaferia, G; Erzegovesi, S; Locatelli, M | 1 |
| Cusin, C; Lattuada, E; Lilli, R; Lorenzi, C; Rossini, D; Serretti, A; Smeraldi, E; Zanardi, R | 2 |
| Buitelaar, JK; Lahuis, B; Vorstman, J | 1 |
| Mynors-Wallis, LM; Thornett, AM | 1 |
| Coolen, LM; Olivier, B; Pattij, T; van De Plas, A; van Oorschot, R; Veening, JG; Waldinger, MD | 1 |
| De Groote, L; Olivier, B; Westenberg, HG | 1 |
| Cullen, N; Lexell, J; Zafonte, RD | 1 |
| Droogmans, G; Maertens, C; Nilius, B; Verbesselt, R | 1 |
| Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J | 1 |
| Fujishiro, J; Imanishi, T; Onozawa, K; Tsushima, M | 1 |
| Entsuah, R; Rudolph, RL; Stahl, SM | 1 |
| Anderson, TA; Dobscha, SK; Hauser, P; Hoffman, WF; Snodgrass, LS; Turner, EH; Winterbottom, LM | 1 |
| Denys, D; van Megen, HJ; Westenberg, HG | 1 |
| Koyama, T; Suzuki, K | 1 |
| Koga, M | 1 |
| Ohmori, T; Sumitani, S | 1 |
| Kiriike, N | 1 |
| Arita, S; Morishita, S | 4 |
| Murakami, N; Nagai, T; Narita, N; Sakuta, R; Tazoe, M | 1 |
| Broocks, A; Hohagen, F; Kordon, A | 1 |
| Masuda, Y; Shimizu, T | 1 |
| Fujii, Y; Iwamura, Y; Kamei, C | 1 |
| Almarza, E; Martínez, MA; Sánchez de la Torre, C | 1 |
| Ben-Amir, E; Doljansky, J; Flaisher, S; Joel, D | 1 |
| Artioli, P; Cusin, C; Dotoli, D; Rossini, D; Serretti, A; Zanardi, R | 1 |
| Eichner, SF; Jones, JR; Moore, ML | 1 |
| Imanishi, T; Kojima, M; Nagase, K; Tatebayashi, T; Yamauchi, M | 1 |
| Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
| Armbrust, KL; Black, MC; Henry, TB; Kwon, JW | 1 |
| Hirano, K; Kagawa, Y; Kimura, R; Maruyama, S; Yamada, S | 1 |
| Albert, U; Bogetto, F; Maina, G; Salvi, V | 1 |
| Hashimoto, H; Hirano, K; Kato, Y; Kimura, R; Sugimoto, Y; Uchida, S; Yamada, J; Yamada, S | 1 |
| Arima, Y; Kubo, C; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Cools, AR; de Jong, TR; Olivier, B; Pattij, T; Veening, JG; Waldinger, MD | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Azuma, J; Fukuda, K; Fukuda, T; Ikenaga, Y; Kato, M; Kinoshita, T; Nobuhara, K; Okugawa, G; Wakeno, M | 1 |
| Benedetti, F; Colombo, C; Cusin, C; Mandelli, L; Pirovano, A; Serretti, A; Smeraldi, E; Zanardi, R | 1 |
| Asai, Y; Ichimiya, T; Inoue, M; Koyama, T; Kusumi, I; Sudo, Y; Suhara, T; Takahashi, Y; Takano, A; Yasuno, F | 1 |
| Cools, AR; de Jong, TR; Olivier, B; Pattij, T; Snaphaan, LJ; Veening, JG; Waldinger, MD | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Carrasco, JL; Sandner, C | 1 |
| Arias, B; Catalán, R; Fañanás, L; Gastó, C; Lorenzi, C; Serretti, A | 1 |
| Imanishi, T; Matsushima, T; Miyara, T; Yamauchi, M | 1 |
| Azuma, N; Fujii, Y; Kamei, C; Kitazumi, K; Shinomiya, K; Sugimoto, Y; Tokunaga, S | 1 |
| Abraham, G; Milev, R; Stuart Lawson, J | 1 |
| Berger, U; Jensen, E; Kallenborn, R; Samuelsen, PJ; Vasskog, T | 1 |
| Belmaker, RH; Nemets, B; Shapira, B; Trachtenberg, A | 1 |
| Azuma, J; Fukuda, K; Fukuda, T; Ikenaga, Y; Kato, M; Kinoshita, T; Nobuhara, K; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M | 1 |
| Kobayashi, T; Ohtsuki, K; Onogi, T; Satoh, K; Takano, S | 1 |
| Bailly, D | 1 |
| Harada, M; Kubo, H; Ohmori, T; Sumitani, S | 1 |
| Nakamura, J; Shinkai, K; Toyohira, Y; Tsutsui, M; Ueno, S; Yanagihara, N; Yoshimura, R | 1 |
| Ahn, SC; Choi, TK; Lee, SH; Lee, YJ; Suh, SY; Yook, KH | 1 |
| Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R; Orito, K | 1 |
| Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R | 1 |
| Mitsuya, H; Murata, T; Murayama, J; Takahashi, T; Wada, Y | 1 |
| Fujisaki, M; Hashimoto, K; Ishii, K; Ishikawa, M; Ishiwata, K; Iyo, M; Kimura, Y; Miyatake, R; Naganawa, M; Oda, K; Sakata, M; Shimizu, E; Shirayama, Y | 1 |
| Ikenouchi-Sugita, A; Nakamura, J; Yoshimura, R | 1 |
| Nomura, S; Sato, Y; Shigemura, J; Yoshino, A | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
| Ikeda, A; Ueki, M; Ushiroyama, T | 1 |
| Egawa, T; Ikeda, M; Kataoka, Y; Koga, A; Shuto, H; Sohda, Y; Tominaga, K; Yamauchi, A | 1 |
| Chihara, K; Hashimoto, K; Ishii, K; Ishikawa, M; Ishiwata, K; Kimura, Y; Naganawa, M; Oda, K; Sakata, M | 1 |
| Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Okugawa, G; Serretti, A; Takekita, Y; Wakeno, M | 1 |
| Ağargün, MY; Aşkin, R; Aydin, A; Beşiroğlu, L; Uğuz, F; Yilmaz, E | 1 |
| Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R | 1 |
| Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Abe, H; Ikeda, T; Ishida, Y; Nakamura, T; Naono, R; Nishimori, T; Takeda, R | 1 |
| Amitani, H; Asakawa, A; Fujimiya, M; Fujitsuka, N; Hayashi, M; Inui, A; Kojima, S; Sameshima, M | 1 |
| Böckenholt, B; Heuft, G; Luger, TA; Schneider, G; Schürmeyer-Horst, F; Ständer, S; Weishaupt, C | 1 |
| Andersohn, F; Garbe, E; Schade, R; Suissa, S | 1 |
| Colombo, C; De Ronchi, D; Kato, M; Kinoshita, T; Okugawa, G; Rossini, D; Serretti, A; Zanardi, R | 1 |
| Imai, T; Inoue, K; Nagata, K; Tozaki-Saitoh, H; Tsuda, M; Yamashita, T | 1 |
| Hayashida, K; Kiriike, N; Matsunaga, H; Nagata, T; Ohya, K; Stein, DJ | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Iwata, N; Kawashima, K; Kinoshita, Y; Kishi, T; Kitajima, T; Naitoh, H; Nakamura, J; Okochi, T; Okumura, T; Ozaki, N; Tsunoka, T; Yamanouchi, Y; Yoshimura, R | 1 |
| Brophy, JM; Etminan, M; Mikelberg, FS | 1 |
| Charles, D; Fava, M; Papakostas, GI | 1 |
| Dormuth, CR; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Hayashida, K; Kiriike, N; Matsunaga, H; Nagata, T; Stein, DJ | 1 |
| Dormuth, C; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Kato, M | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Mochcovitch, MD; Nardi, AE | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Corona, T; Fornai, M; Mantarro, S; Montagnani, S; Pergola, A; Ruggiero, E; Scollo, C; Testi, A; Tuccori, M | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Bhuiyan, S; Fukunaga, K; Hasegawa, H; Kanai, H; Shioda, N; Tagashira, H | 1 |
| Boku, S; Inoue, T; Izumi, T; Kakuta, A; Kitaichi, Y; Koyama, T; Nakagawa, S | 1 |
| Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Dobzhenko, MN; Shchepotin, IB; Zotov, AS | 1 |
| Fukuo, Y; Inada, T; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Kushima, I; Matsunaga, S; Naitoh, H; Nakamura, J; Okochi, T; Ozaki, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Azuma, J; Fujiwara, T; Hara, S; Hasunuma, T; Higashi, K; Katano, T; Kitahara, S; Koue, T; Kubo, M; Miyatake, M | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Nagata, T; Nakajima, T; Teo, AR; van Vliet, I; Yamada, H; Yoshimura, C | 1 |
| Hotta, Y; Kobayashi, Y; Mitsui-Saitoh, K; Sugimoto, Y; Tagawa, N; Yamada, J; Yamamoto, M | 1 |
| Fukunaga, K; Tagashira, H | 1 |
| Akamine, Y; Kaneko, S; Niioka, T; Saruwatari, J; Takashima, A; Uno, T; Yasui-Furukori, N | 1 |
| Mandrioli, R; Mercolini, L; Raggi, MA; Saracino, MA | 1 |
| Gotzlav, Y; Iancu, I; Kertzman, S; Kotler, M; Reznik, I; Vainder, M; Weizman, A | 1 |
| Azuma, J; Hasegawa, R; Hiratsuka, K; Ishiwata, K; Kato, M; Kinoshita, T; Kurosawa, T; Kurose, K; Nishikawa, J; Nonen, S; Okugawa, G; Saito, Y; Wakeno, M | 1 |
| Boku, S; Fujisawa, D; Honda, M; Inoue, T; Ishikane, T; Ito, K; Kawamura, K; Koyama, T; Matsubara, R; Ono, Y; Sasaki, K; Shinohara, K; Suzuki, T; Tsuchiya, K | 1 |
| Hotta, Y; Kobayashi, Y; Mitsui-Saito, K; Sugimoto, Y; Tagawa, N; Yamada, J | 1 |
| Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Tetsuo, S | 1 |
| Gorman, DA; Lam, D; Patten, S; Pringsheim, T | 1 |
| Fukunaga, K; Han, F; Izumi, H; Moriguchi, S; Sakagami, H; Sasaki, Y; Yabuki, Y; Zhang, C | 1 |
| Hermann, M; Molden, E; Waade, RB | 1 |
| Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N | 1 |
| Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
| Ago, Y; Hasebe, S; Hashimoto, H; Matsuda, T; Nishiyama, S; Oka, S; Takuma, K | 1 |
| Halling-Sørensen, B; Hansen, CH; Jacobsen, NW; Nellemann, C; Styrishave, B | 1 |
| Egashira, N; Kuwahara, J; Masuda, S; Ueda, M; Ushio, S; Yamada, T; Zukeyama, N | 1 |
| Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL | 1 |
| Li, Y; Lu, X; Tao, C; Yan, W | 1 |
| Casavant, MJ; Chounthirath, T; Russell, JL; Spiller, HA | 1 |
| Brekke, M; Molden, E; Skogvoll, E; Spigset, O; Westin, AA | 1 |
| Araujo, M; Benevent, J; Bondon-Guitton, E; Chebane, L; Durrieu, G; Montastruc, F; Montastruc, JL; Ojero-Senard, A | 1 |
| Biber, K; Bischofberger, J; Clark, K; Dorner, A; Frase, S; Haug, V; Horn, M; Klugbauer, N; Münzer, P; Nissen, C; Normann, C; Scholliers, J; Seifert, G; Serchov, T; Vo Van, T; von Wolff, G | 1 |
| Coleman, JA; Gouaux, E | 1 |
| Arnold, PD; Bousman, C; Greenslade, A; Maruf, AA | 1 |
| Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Ogata, H; Sunada, N; Takekita, Y; Wakeno, M | 1 |
| Liao, XM; Si, TM; Su, YA; Wang, Y; Yu, X | 1 |
| Hui, A | 1 |
| Chen, L; Feng, X; Huang, C; Shen, X; Wang, J; Xu, T | 1 |
| Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA | 1 |
| Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Gaynes, BN; Pun, PH; Winkelmayer, WC | 1 |
| Azoulay, L; Cao, TXD; Fergusson, E; Filliter, C; Montastruc, F; Rej, S; Renoux, C; Yu, OHY | 1 |
| Bayati, R; Ghaffari Jolfayi, A; Nakhaee, H; Rahmanian, M; Rakhshanderou, S; Zangiabadian, M | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Kodvanj, I; Trkulja, V | 1 |
| Cai, W; Jiang, D; Liang, H; Lin, Q; Lin, Y; Wang, Y | 1 |
| Blakely, RD; Groshan, K; Richelson, E; Tatsumi, M | 1 |
60 review(s) available for paroxetine and fluvoxamine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Depressive Disorder; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1992 |
Pharmacokinetics of the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
Pharmacotherapy of obsessive compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; Paroxetine; Piperidines; Serotonin; Sertraline | 1992 |
5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour.
Topics: Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Mianserin; Paroxetine; Piperidines; Serotonin Antagonists; Suicide; Suicide Prevention | 1991 |
Biochemical pharmacology of the serotonin system.
Topics: Alanine; Brain; Citalopram; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Neurons; Oximes; p-Chloroamphetamine; Paroxetine; Piperidines; Propylamines; Receptors, Serotonin; Reserpine; Serotonin; Serotonin Antagonists; Synapses; Tetrabenazine; Zimeldine | 1986 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Propylamines; Serotonin; Serotonin Antagonists; Trazodone; Zimeldine | 1986 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stereoisomerism | 1995 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
[Clinical effects of serotonin reuptake inhibitors--a review].
Topics: Depression; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1994 |
The pharmacogenetics of the selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors | 1993 |
[New antidepressive agents].
Topics: 1-Naphthylamine; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Child; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Moclobemide; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
Use of serotonin selective reuptake inhibitors in geriatric depression.
Topics: 1-Naphthylamine; Age Factors; Aged; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Female; Fluoxetine; Fluvoxamine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I.
Topics: Cytochrome P-450 CYP1A1; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Isoenzymes; Microsomes, Liver; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Topics: 1-Naphthylamine; Animals; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Movement disorders associated with the serotonin selective reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Age Factors; Aged; Akathisia, Drug-Induced; Depressive Disorder; Dyskinesia, Drug-Induced; Dystonia; Female; Fluoxetine; Fluvoxamine; Humans; Male; MEDLINE; Middle Aged; Parkinson Disease, Secondary; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; United States | 1996 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
Topics: 1-Naphthylamine; Chromatography; Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Topics: 1-Naphthylamine; Antidepressive Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
SSRI safety in overdose.
Topics: Adult; Child; Citalopram; Drug Overdose; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Poison Control Centers; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1998 |
Current concepts in the treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Pharmacokinetics of selective serotonin reuptake inhibitors.
Topics: Citalopram; Clinical Trials as Topic; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
Psychopharmacologic treatment of adolescent depression.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2001 |
[Early internal treatment of mild depression].
Topics: Depression; Fluvoxamine; Health Knowledge, Attitudes, Practice; Humans; Paroxetine; Physicians, Family; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Social Support; Suicide Prevention | 2001 |
Serotonin agents in the treatment of acquired brain injury.
Topics: Brain Injuries; Citalopram; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Injury Severity Score; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2002 |
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
[Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Fluvoxamine; Humans; Isoenzymes; Lithium; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2003 |
[Panic disorder and agoraphobia].
Topics: Agoraphobia; Cognitive Behavioral Therapy; Diagnosis, Differential; Diagnostic and Statistical Manual of Mental Disorders; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Reference Standards; Selective Serotonin Reuptake Inhibitors | 2003 |
[The treatment of OCD].
Topics: Antipsychotic Agents; Behavior Therapy; Clomipramine; Drug Therapy, Combination; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Obsessive-Compulsive Disorder; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors | 2003 |
[Eating disorders].
Topics: Comorbidity; Feeding and Eating Disorders; Fluvoxamine; Humans; Nutritional Support; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Reference Standards; Selective Serotonin Reuptake Inhibitors; Serotonin | 2003 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Citalopram; Clomipramine; Depression; Diagnosis, Differential; Eczema; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires; Time Factors; Trichotillomania | 2003 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Child, Preschool; Citalopram; Confidence Intervals; Depressive Disorder; Family Practice; Female; Fluoxetine; Fluvoxamine; History, Medieval; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Placebos; Psychotherapy; Randomized Controlled Trials as Topic; Risk; Safety; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Suicide; Suicide, Attempted | 2006 |
[Review of pharmacological efficacies and side effects of antidepressants].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Fluvoxamine; Humans; Imipramine; Maprotiline; Paroxetine; Sulpiride; Trazodone | 2007 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Topics: Adult; Citalopram; Female; Fluoxetine; Fluvoxamine; Humans; Odds Ratio; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2008 |
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
[Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fibroblast Growth Factor 2; Fluvoxamine; Forecasting; Humans; Meta-Analysis as Topic; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Racial Groups; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins | 2010 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Maternal-Fetal Exchange; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Teratogens | 2010 |
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
[Cardioprotective effect of fluvoxamine, sigma-1 receptor high affinity agonist].
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Disease Models, Animal; Fluvoxamine; Heart Ventricles; Male; Mice; Mice, Inbred ICR; Nitric Oxide Synthase Type III; Paroxetine; Proto-Oncogene Proteins c-akt; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sigma-1 Receptor; Signal Transduction | 2012 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indoles; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Vilazodone Hydrochloride | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2016 |
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mental Disorders; Nortriptyline; Paroxetine; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2019 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desvenlafaxine Succinate; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Psychometrics; Sertraline; Treatment Outcome | 2020 |
Recent sample pretreatment methods for determination of selective serotonin reuptake inhibitors (SSRIs) in biological samples.
Topics: Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Topics: Antidepressive Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
37 trial(s) available for paroxetine and fluvoxamine
| Article | Year |
|---|---|
The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability.
Topics: Adult; Aged; Amitriptyline; Depressive Disorder; Dose-Response Relationship, Drug; Doxepin; Drug Administration Schedule; Electrocardiography; Female; Fluvoxamine; Heart Rate; Humans; Male; Middle Aged; Paroxetine | 1994 |
Response to an open trial of a second SSRI in major depression.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
Personality disorder scores improve with effective pharmacotherapy of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Ergolines; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Disorders; Personality Inventory; Serotonin Antagonists | 1997 |
A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Fluvoxamine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Sweating; Treatment Outcome; Xerostomia | 1997 |
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Female; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Smoking | 1998 |
Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Topics: Adult; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Pindolol; Placebos; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1999 |
CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Topics: Adult; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Reference Values; Sertraline | 1999 |
Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care.
Topics: Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder; Fluvoxamine; Humans; Middle Aged; Paroxetine; Problem Solving; Psychotherapy; Treatment Outcome | 2000 |
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Libido; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires; Time Factors | 2000 |
Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 2000 |
[What is the "best" treatment of depression in general practice?].
Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Family Practice; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Patient Care Team; Personality Inventory; Problem Solving; Treatment Outcome | 2000 |
Neurophysiologic tests during antidepressive treatment - an exploratory study.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Depressive Disorder, Major; Doxepin; Female; Fluvoxamine; Heart Rate; Humans; Male; Middle Aged; Neural Conduction; Paroxetine; Psychometrics; Reaction Time; Reflex; Selective Serotonin Reuptake Inhibitors | 2000 |
Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal.
Topics: Adult; Circadian Rhythm; Drug Administration Schedule; Equipment Design; Eyelids; Female; Fluvoxamine; Head; Humans; Longitudinal Studies; Male; Monitoring, Ambulatory; Monitoring, Physiologic; Movement; Paroxetine; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Stages; Sleep, REM; Substance Withdrawal Syndrome | 2001 |
Credibility of problem-solving therapy and medication for the treatment of depression among primary care patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Psychotherapeutic Processes; Time Factors; Treatment Outcome | 2002 |
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Antimanic Agents; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lithium; Male; Middle Aged; Monoamine Oxidase; Paroxetine; Pindolol; Polymorphism, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sex Characteristics | 2002 |
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Topics: Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Fluvoxamine; Genotype; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; DNA; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Mood Disorders; Nerve Tissue Proteins; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Tryptophan Hydroxylase | 2004 |
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chi-Square Distribution; Cohort Studies; Cyclopropanes; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obesity; Obsessive-Compulsive Disorder; Paroxetine; Patient Compliance; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2004 |
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
Topics: Adult; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Fluvoxamine; Genotype; Heterozygote; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Patient Dropouts; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2005 |
Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism.
Topics: Adult; Aged; Antidepressive Agents; CLOCK Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Male; Middle Aged; Mood Disorders; Multivariate Analysis; Paroxetine; Pindolol; Polymorphism, Genetic; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Time Factors; Trans-Activators; Treatment Outcome | 2005 |
T3 augmentation of SSRI resistant depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Resistance; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Triiodothyronine | 2006 |
Phenytoin as an augmentation for SSRI failures: a small controlled study.
Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phenytoin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Combined Modality Therapy; Fluvoxamine; Humans; Meditation; Paroxetine; Program Development; Self Care; Sertraline; Stress, Psychological; Surveys and Questionnaires | 2007 |
Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluvoxamine; Humans; Menopause; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cognitive Behavioral Therapy; Combined Modality Therapy; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Fluvoxamine; Follow-Up Studies; Humans; Long-Term Care; Male; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2009 |
Clinical features and treatment characteristics of compulsive hoarding in Japanese patients with obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Compulsive Behavior; Female; Fluvoxamine; Humans; Japan; Male; Obsessive-Compulsive Disorder; Paroxetine; Prevalence; Psychiatric Status Rating Scales; Psychometrics; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2010 |
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Genetic Association Studies; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Paroxetine; Piperazines; Polymorphism, Genetic; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Young Adult | 2012 |
Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Drug Interactions; Female; Fluvoxamine; Half-Life; Humans; Intestine, Small; Liver; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Terfenadine; Young Adult | 2012 |
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Severity of Illness Index; Treatment Outcome | 2012 |
5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
Topics: Analysis of Variance; Antidepressive Agents; Depression; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Japan; Logistic Models; Male; Paroxetine; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Serotonin Plasma Membrane Transport Proteins; Time Factors; Treatment Outcome | 2013 |
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Topics: Age Factors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Female; Fibroblast Growth Factors; Fluvoxamine; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome | 2015 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
147 other study(ies) available for paroxetine and fluvoxamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Ligands; Models, Molecular; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2021 |
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sparteine | 1992 |
Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
Topics: Amino Acid Sequence; Animals; Antidepressive Agents, Second-Generation; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Cerebral Cortex; Cyclohexanols; Cytosol; Fluvoxamine; Hippocampus; Male; Molecular Sequence Data; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Phosphorylation; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Synaptosomes; Time Factors; Venlafaxine Hydrochloride | 1995 |
The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.
Topics: 1-Naphthylamine; Animals; Appetite Depressants; Brain Chemistry; Eating; Fluoxetine; Fluvoxamine; Hydroxyindoleacetic Acid; Indoles; Male; Paroxetine; Rats; Rats, Inbred Strains; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1993 |
Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
Topics: 1-Naphthylamine; 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Analysis of Variance; Animals; Behavior, Animal; Brain; Citalopram; Dose-Response Relationship, Drug; Fenclonine; Fluoxetine; Fluvoxamine; Male; Mice; Paroxetine; Penbutolol; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Sertraline; Synaptosomes | 1994 |
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
Topics: Alprazolam; Biotransformation; Culture Techniques; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Dose-Response Relationship, Drug; Fluvoxamine; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1995 |
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning.
Topics: Analysis of Variance; Animals; Conditioning, Psychological; Disease Models, Animal; Drug Administration Schedule; Fluvoxamine; Injections, Subcutaneous; Male; Morphine; Naloxone; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance Withdrawal Syndrome; Substance-Related Disorders | 1995 |
[Antidepressive agents with only few serious adverse effects].
Topics: Antidepressive Agents; Drug Interactions; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1993 |
Serotonin syndrome and fluvoxamine: a case study.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Psychoses, Substance-Induced; Selective Serotonin Reuptake Inhibitors; Syndrome; Time Factors | 1996 |
Potential withdrawal syndrome associated with SSRI discontinuation.
Topics: 1-Naphthylamine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1995 |
Effect of fluvoxamine on 5-hydroxytryptamine uptake, paroxetine binding sites and ketanserin binding sites in the Japanese monkey brain and platelets, in vivo and in vitro.
Topics: Animals; Binding, Competitive; Blood Platelets; Brain; Cerebral Cortex; Fluvoxamine; In Vitro Techniques; Ketanserin; Macaca; Male; Paroxetine; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin | 1996 |
Serotonin reuptake inhibitor withdrawal.
Topics: 1-Naphthylamine; Adolescent; Adult; Age Factors; Clomipramine; Dizziness; Female; Fluvoxamine; Humans; Male; Middle Aged; Paresthesia; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Substance Withdrawal Syndrome | 1996 |
Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.
Topics: 1-Naphthylamine; Aged; Anorexia; Antidepressive Agents; Depressive Disorder; Diarrhea; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Nausea; Paroxetine; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Sertraline; Single-Blind Method | 1996 |
[Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Belgium; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Effects of antidepressants on the cytochrome P450 system.
Topics: 1-Naphthylamine; Antidepressive Agents; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Medical Records; Paroxetine; Research Design; Sertraline | 1996 |
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1996 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sertraline; Vocalization, Animal | 1997 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
Vitamin C for paroxetine- and fluvoxamine-associated bleeding.
Topics: Adult; Ascorbic Acid; Ecchymosis; Female; Fluvoxamine; Hemorrhage; Humans; Menorrhagia; Panic Disorder; Paroxetine | 1997 |
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Fluoxetine; Fluvoxamine; Frozen Sections; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Lethal Dose 50; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Venlafaxine Hydrochloride | 1997 |
The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval.
Topics: 1-Naphthylamine; Animals; Dopamine; Dose-Response Relationship, Drug; Fluvoxamine; Male; Membrane Potentials; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sertraline; Tegmentum Mesencephali | 1997 |
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
Topics: 1-Naphthylamine; Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Cohort Studies; Female; Fluvoxamine; Humans; Infant, Newborn; Paroxetine; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Female; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Risk of fetal anomalies with exposure to selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Antidepressive Agents; Female; Fluvoxamine; Humans; Paroxetine; Pregnancy; Pregnancy Outcome; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area.
Topics: Adrenergic beta-Antagonists; Animals; Dopamine; Dose-Response Relationship, Drug; Electrophysiology; Fluvoxamine; Male; Membrane Potentials; Neurons; Paroxetine; Propanolamines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Thiophenes; Ventral Tegmental Area | 1998 |
[Withdrawal symptoms in connection with the use of selective serotonin reuptake inhibitors (SSRI)].
Topics: Adult; Antidepressive Agents; Citalopram; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; Fluoxetine; Fluvoxamine; Food Preferences; Male; Paroxetine; Rats; Rats, Mutant Strains; Selective Serotonin Reuptake Inhibitors | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Humans; Lactation; Milk, Human; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Triglycerides | 1999 |
[Severe withdrawal symptoms with fever upon stopping paroxetine].
Topics: Citalopram; Drug Administration Schedule; Fever; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1999 |
Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Carrier Proteins; Desipramine; Fluvoxamine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Paroxetine; Phenelzine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Time Factors | 1999 |
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluorometry; Fluoxetine; Fluvoxamine; Humans; Linear Models; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline | 2000 |
[Tourette's syndrome and antidepressant therapy: exacerbation of nervous tics with paroxetine].
Topics: Antidepressive Agents, Tricyclic; Child; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tics; Tourette Syndrome; Treatment Outcome; Trimipramine | 2000 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Modification of presynaptic CaM kinase II affinity for ATP in hippocampus after long term blockade of serotonin reuptake.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents, Second-Generation; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Fluvoxamine; Hippocampus; Kinetics; Male; Paroxetine; Phosphorylation; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2000 |
Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Topics: Adult; Antidepressive Agents; Cross-Sectional Studies; Drug Costs; Fluoxetine; Fluvoxamine; Forecasting; Humans; Insurance Claim Reporting; Insurance, Pharmaceutical Services; Middle Aged; Models, Theoretical; Ontario; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects.
Topics: Adult; Dreams; Female; Fluvoxamine; Humans; Male; Mental Recall; Paroxetine; Periodicity; Random Allocation; Selective Serotonin Reuptake Inhibitors; Sleep, REM; Surveys and Questionnaires | 2001 |
[The transfer of selective serotonin reuptake inhibitors to human milk].
Topics: Antidepressive Agents; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Milk, Human; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Use of sertraline, paroxetine and fluvoxamine by nursing women.
Topics: Breast Feeding; Chromatography, High Pressure Liquid; Depression, Postpartum; Female; Fluvoxamine; Humans; Infant, Newborn; Paroxetine; Regression Analysis; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Child; Child, Preschool; Clinical Trials as Topic; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Topics: Animals; Binding, Competitive; Body Temperature; Brain; Cerebral Cortex; Fluoxetine; Fluvoxamine; Indoles; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Paroxetine; Rats; Rectum; Serotonin; Serotonin Agents; Time Factors; Tritium | 2001 |
Clinical predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Citalopram; Clomipramine; Drug Resistance; Female; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Predictive Value of Tests; Psychological Tests; Random Allocation; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors.
Topics: Depressive Disorder, Major; Exons; Female; Fluvoxamine; Gene Expression; Gene Frequency; Humans; Male; Middle Aged; Paroxetine; Receptors, Dopamine D2; Receptors, Dopamine D4; Selective Serotonin Reuptake Inhibitors | 2001 |
SSRIs associated with behavioral activation and suicidal ideation.
Topics: Attention Deficit and Disruptive Behavior Disorders; Child; Depressive Disorder, Major; Fluvoxamine; Humans; Male; Paroxetine; Suicide, Attempted | 2001 |
The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment.
Topics: Animals; Ejaculation; Female; Fluvoxamine; Male; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sexual Behavior, Animal | 2002 |
The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice.
Topics: Animals; Dose-Response Relationship, Drug; Extracellular Space; Fluvoxamine; Genotype; Hippocampus; Injections, Intraperitoneal; Mice; Mice, Inbred Strains; Mice, Knockout; Microdialysis; Paroxetine; Pyridines; Pyrroles; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Time Factors | 2002 |
Block of volume-regulated anion channels by selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Cells, Cultured; Chloride Channels; Citalopram; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluvoxamine; Humans; Hydrogen-Ion Concentration; Hypotonic Solutions; Inhibitory Concentration 50; Membrane Potentials; Paroxetine; Patch-Clamp Techniques; Pulmonary Artery; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Cholinergic Antagonists; Clomipramine; Defecation; Fluvoxamine; Immobilization; Mice; Mice, Inbred ICR; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration Schedule; Drug Costs; Drug Utilization; Fluoxetine; Fluvoxamine; Hospital Costs; Hospitals, Veterans; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2003 |
Drug-related hyperprolactinemia.
Topics: Antidepressive Agents; Antipsychotic Agents; Female; Flunarizine; Fluoxetine; Fluvoxamine; Humans; Hyperprolactinemia; Indoramin; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sulpiride | 2003 |
Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care.
Topics: Adult; Female; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Skin | 2003 |
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Topics: Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome | 2003 |
[Anxiety in school refusal children with indefinite complaints: psychological estimation using State-Trait Anxiety Inventory and therapy by serotonin reuptake inhibitors].
Topics: Adolescent; Anxiety; Child; Female; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Student Dropouts; Treatment Outcome | 2003 |
Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Personality Inventory; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome | 2003 |
Different effects of selective serotonin reuptake inhibitors on a patient suffering from panic disorder.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Hypnotics and Sedatives; Male; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
The effects of selective serotonin-reuptake inhibitor on visual evoked potential in rats.
Topics: Administration, Oral; Animals; Data Display; Evoked Potentials, Visual; Fluvoxamine; Male; Occipital Lobe; Oscillometry; Paroxetine; Photic Stimulation; Rats; Rats, Wistar; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Stereotaxic Techniques | 2004 |
A comparative solid-phase extraction study for the simultaneous determination of fluvoxamine, mianserin, doxepin, citalopram, paroxetine, and etoperidone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, Gas; Chromatography, Liquid; Citalopram; Doxepin; Female; Fluvoxamine; Humans; Mianserin; Nitrogen; Paroxetine; Phosphorus; Reproducibility of Results; Trazodone | 2004 |
'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Compulsive Behavior; Conditioning, Operant; Desipramine; Diazepam; Dose-Response Relationship, Drug; Extinction, Psychological; Fluvoxamine; Male; Paroxetine; Rats; Rats, Wistar; Reward; Selective Serotonin Reuptake Inhibitors | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; France; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Fluvoxamine; Hypokinesia; Male; Motor Activity; Paroxetine; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia.
Topics: Animals; Citalopram; Cladocera; Ecosystem; Female; Fluoxetine; Fluvoxamine; Lethal Dose 50; Male; No-Observed-Adverse-Effect Level; Paroxetine; Reproduction; Selective Serotonin Reuptake Inhibitors; Sertraline; Toxicity Tests, Acute; Toxicity Tests, Chronic; Water Pollutants, Chemical | 2004 |
In vivo identification and characterization of binding sites for selective serotonin reuptake inhibitors in mouse brain.
Topics: Analysis of Variance; Animals; Area Under Curve; Binding Sites; Brain; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Paroxetine; Radioligand Assay; Receptors, Serotonin; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Tritium | 2004 |
Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
Topics: Cohort Studies; Cyclopropanes; Depression; Drug Administration Schedule; Fluvoxamine; Humans; Milnacipran; Paroxetine; Psychomotor Agitation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2004 |
Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Topics: Animals; Behavior, Animal; Binding Sites; Brain; Fluoxetine; Fluvoxamine; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred ICR; Motor Activity; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2005 |
Improvement of dry mouth by replacing paroxetine with fluvoxamine.
Topics: Aged; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Paroxetine; Receptors, Muscarinic; Selective Serotonin Reuptake Inhibitors; Xerostomia | 2005 |
Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Ejaculation; Female; Fluvoxamine; Male; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Behavior, Animal | 2005 |
Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.
Topics: Adult; Antipsychotic Agents; Carbon Isotopes; Chromatography, High Pressure Liquid; Clozapine; Computer Simulation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Fluvoxamine; Humans; Male; Paroxetine; Positron-Emission Tomography; Pyrrolidines; Receptors, Dopamine D2; Salicylamides; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Time Factors | 2006 |
Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Dose-Response Relationship, Radiation; Drug Interactions; Fluvoxamine; Inhibition, Psychological; Male; Maze Learning; Paroxetine; Rats; Rats, Wistar; Reaction Time; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Sexual Behavior, Animal; Swimming | 2006 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
Topics: Antidepressive Agents, Second-Generation; Biological Availability; Catechol O-Methyltransferase; Citalopram; Depressive Disorder, Major; Dopamine; Ethnicity; Female; Fluvoxamine; Follow-Up Studies; Frontal Lobe; Genetic Carrier Screening; Genotype; Humans; Male; Methionine; Paroxetine; Personality Inventory; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Valine | 2006 |
Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors.
Topics: Animals; Corticosterone; Fluvoxamine; Ketanserin; Paroxetine; Rats; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors | 2006 |
Effect of paroxetine on marble-burying behavior in mice.
Topics: Animals; Clomipramine; Dose-Response Relationship, Drug; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2005 |
Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway.
Topics: Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Fluvoxamine; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sewage; Water Pollutants, Chemical | 2006 |
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
Topics: Adult; Antidepressive Agents; Chi-Square Distribution; Depression; Dose-Response Relationship, Drug; Female; Fluvoxamine; Humans; Japan; Male; Middle Aged; Paroxetine; Receptors, Serotonin, 5-HT2; Retrospective Studies; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index | 2006 |
Serotonin syndrome caused by minimum doses of SSRIS in a patient with spinal cord injury.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Spinal Cord Injuries | 2006 |
Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia; Benzodiazepines; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Energy Metabolism; Female; Fluvoxamine; Frontal Lobe; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Nerve Net; Obsessive-Compulsive Disorder; Olanzapine; Paroxetine; Prefrontal Cortex; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran.
Topics: Adrenal Medulla; Animals; Antidepressive Agents; Butadienes; Catecholamines; Cattle; Cells, Cultured; Cyclopropanes; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Enzyme Activation; Fluvoxamine; Milnacipran; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Paroxetine; Phosphorylation; Protein Kinase Inhibitors; Selective Serotonin Reuptake Inhibitors; Time Factors; Tyrosine; Tyrosine 3-Monooxygenase | 2007 |
Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine.
Topics: Animals; Behavior, Animal; Brain; Butyrates; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Morpholines; Obsessive-Compulsive Disorder; Paroxetine; Phenazocine; Piperazines; Psychotropic Drugs; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sigma-1 Receptor; Tropanes | 2007 |
Antidepressant response in the elderly.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Opposite effects of SSRIs and tandospirone in the treatment of REM sleep behavior disorder.
Topics: Aged; Female; Fluvoxamine; Humans; Isoindoles; Paroxetine; Piperazines; Polysomnography; Pyrimidines; Reaction Time; REM Sleep Behavior Disorder; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sleep, REM; Treatment Outcome | 2008 |
High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503.
Topics: Adult; Brain; Dose-Response Relationship, Drug; Fluvoxamine; Humans; Male; Paroxetine; Piperazines; Polymorphism, Single Nucleotide; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sigma-1 Receptor | 2007 |
Patient satisfaction with antidepressants: an Internet-based study.
Topics: Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Data Collection; Depressive Disorder, Major; Fluvoxamine; Humans; Internet; Japan; Logistic Models; Milnacipran; Paroxetine; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2008 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice.
Topics: Animals; Dose-Response Relationship, Drug; Estradiol; Estrogens; Female; Fluvoxamine; Hot Flashes; Humans; Menopause; Mice; Mice, Inbred ICR; Models, Animal; Ovariectomy; Paroxetine; Physical Conditioning, Animal; Selective Serotonin Reuptake Inhibitors; Skin Temperature; Tail | 2008 |
Shortened protocol in practical [11C]SA4503-PET studies for sigma1 receptor quantification.
Topics: Adult; Brain Chemistry; Brain Mapping; Carbon Radioisotopes; Clinical Protocols; Fluvoxamine; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Isotope Labeling; Male; Paroxetine; Piperazines; Positron-Emission Tomography; Radioligand Assay; Radiopharmaceuticals; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Tissue Distribution | 2008 |
Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Genotype; Heterotrimeric GTP-Binding Proteins; Humans; Japan; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2008 |
[Psychopharmacological treatment and quality of life in obsessive compulsive disorder].
Topics: Adult; Female; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2008 |
A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Paroxetine | 2009 |
Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain.
Topics: Analgesics; Animals; Antidepressive Agents; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Fluvoxamine; Hyperalgesia; Injections, Spinal; Male; Milnacipran; Pain Threshold; Paroxetine; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Selective Serotonin Reuptake Inhibitors; Serotonin; Spinal Cord | 2009 |
Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin.
Topics: Animals; Drugs, Chinese Herbal; Eating; Fenfluramine; Fluoxetine; Fluvoxamine; Gastrointestinal Motility; Ghrelin; Growth Hormone; Injections, Intraventricular; Male; Oligopeptides; Paroxetine; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Ghrelin; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2009 |
Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Chronic Disease; Dermatitis, Atopic; Female; Fluvoxamine; Humans; Lymphoma; Male; Middle Aged; Paroxetine; Prospective Studies; Pruritus; Selective Serotonin Reuptake Inhibitors | 2009 |
Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Body Mass Index; Case-Control Studies; Cyclohexanols; Depressive Disorder; Diabetes Mellitus; Female; Fluvoxamine; Humans; Incidence; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Time Factors; United Kingdom; Venlafaxine Hydrochloride | 2009 |
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients.
Topics: Adult; Antidepressive Agents; Asian People; Depressive Disorder; Depressive Disorder, Major; Female; Fluvoxamine; Gene Frequency; Genetic Variation; Genotype; Humans; Italy; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; White People | 2009 |
Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief.
Topics: Action Potentials; Animals; Antidepressive Agents; Cell Line, Tumor; Citalopram; Disease Models, Animal; Fluvoxamine; Humans; Injections, Spinal; Male; Pain; Pain Measurement; Paroxetine; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2X4; Serotonin Antagonists; Spinal Cord | 2009 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.
Topics: Asian People; Depressive Disorder, Major; Fluvoxamine; Genotype; Haplotypes; Humans; Linkage Disequilibrium; Paroxetine; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study.
Topics: Aged; Case-Control Studies; Cataract; Cataract Extraction; Cyclohexanols; Female; Fluvoxamine; Humans; Male; Paroxetine; Pharmacoepidemiology; Risk Factors; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Suicide Prevention; Suicide, Attempted | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Hospitalization; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Risk; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted | 2010 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice.
Topics: Animals; Aorta; Cells, Cultured; Fluvoxamine; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred ICR; Models, Animal; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Paroxetine; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sigma-1 Receptor; Time Factors; Vasoconstriction; Ventricular Dysfunction, Left | 2010 |
Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.
Topics: Animals; Corpus Striatum; Dopamine; Extracellular Space; Fluvoxamine; Male; Microdialysis; Norepinephrine; Nucleus Accumbens; Paroxetine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 2010 |
Differences in clinical effect and tolerance between fluvoxamine and paroxetine: a switching study in patients with depression.
Topics: Adult; Depression; Depressive Disorder; Drug Substitution; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome; Young Adult | 2010 |
Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population.
Topics: Adult; Asian People; Case-Control Studies; Circadian Clocks; Depressive Disorder, Major; Endopeptidases; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Ubiquitin | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: clinical characteristics and treatment response in a case series.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclopropanes; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluvoxamine; Humans; Interview, Psychological; Japan; Male; Milnacipran; Obsessive-Compulsive Disorder; Paroxetine; Phobic Disorders; Psychotherapy, Group; Reactive Attachment Disorder; Retrospective Studies; Social Isolation; Treatment Outcome; Young Adult | 2013 |
Differences between mice strains in response to paroxetine in the forced swimming test: involvement of serotonergic or noradrenergic systems.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Neurons; Animals; Antidepressive Agents; Behavior, Animal; Dose-Response Relationship, Drug; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Prazosin; Receptors, Serotonin; Serotonergic Neurons; Serotonin Antagonists; Species Specificity; Swimming; Time Factors | 2011 |
Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Israel; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paroxetine; Patient Selection; Personality Assessment; Predictive Value of Tests; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Asian People; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genome-Wide Association Study; Genotype; GPI-Linked Proteins; Humans; Male; Middle Aged; Milnacipran; Neural Cell Adhesion Molecules; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological | 2012 |
Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Fluvoxamine; Male; Mice; Mice, Inbred DBA; Motor Activity; Paroxetine; Receptors, sigma; Sigma-1 Receptor; Swimming | 2012 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; Databases, Factual; Fluoxetine; Fluvoxamine; Humans; Infant; Mental Disorders; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Sertraline | 2013 |
Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; Calbindins; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Dentate Gyrus; Depression; Fluvoxamine; Gene Expression Regulation; Immobilization; Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Knockout; Nerve Tissue Proteins; Neurogenesis; Paroxetine; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Sigma-1 Receptor | 2015 |
Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Child; Citalopram; Databases, Factual; Drug Monitoring; Drug Utilization; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice.
Topics: Animals; Animals, Outbred Strains; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Desipramine; Duloxetine Hydrochloride; Fluvoxamine; Hydroxycorticosteroids; Idazoxan; Indoles; Male; Mice; Motor Activity; Neuropsychological Tests; Oxazines; Paroxetine; Piperazines; Psychotropic Drugs; Pyridines; Risperidone; Ritanserin; Social Behavior; Social Isolation; Sulfonamides; Venlafaxine Hydrochloride | 2015 |
Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay.
Topics: Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Citalopram; Estradiol; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Progesterone; Selective Serotonin Reuptake Inhibitors; Sertraline; Testosterone | 2015 |
Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Citalopram; Cyclopropanes; Duloxetine Hydrochloride; Fluvoxamine; Hep G2 Cells; Humans; Liver Neoplasms; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline | 2015 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fluvoxamine; Hippocampus; Interneurons; Male; Maze Learning; Memory Disorders; Mianserin; Mirtazapine; Paroxetine; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Sertraline; Spatial Memory; Venlafaxine Hydrochloride | 2016 |
Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
Topics: Child; Child, Preschool; Citalopram; Coma; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Hospitalization; Humans; Infant; Male; Paroxetine; Poison Control Centers; Retrospective Studies; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Vilazodone Hydrochloride | 2017 |
Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.
Topics: Adult; Antidepressive Agents; Citalopram; Databases, Factual; Depressive Disorder; Drug Monitoring; Female; Fluvoxamine; Humans; Norway; Paroxetine; Pregnancy; Pregnancy Trimester, Third; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2017 |
A comparative study of QT prolongation with serotonin reuptake inhibitors.
Topics: Adult; Aged; Arrhythmias, Cardiac; Citalopram; Databases, Factual; Female; Fluvoxamine; Humans; Long QT Syndrome; Male; Middle Aged; Paroxetine; Pharmacovigilance; Selective Serotonin Reuptake Inhibitors; Sertraline | 2017 |
Antidepressants Rescue Stress-Induced Disruption of Synaptic Plasticity via Serotonin Transporter-Independent Inhibition of L-Type Calcium Channels.
Topics: Age Factors; Animals; Antidepressive Agents; Cadmium Chloride; Calcium Channel Blockers; Calcium Channels, L-Type; CHO Cells; Cricetulus; Disease Models, Animal; Electric Stimulation; Female; Fluvoxamine; HEK293 Cells; Hindlimb Suspension; Hippocampus; Humans; In Vitro Techniques; Male; Membrane Potentials; Nifedipine; Paroxetine; Patch-Clamp Techniques; Piperazines; Pyridines; Rats; Rats, Transgenic; Rats, Wistar; RNA-Binding Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Stress, Psychological; Swimming; Synaptic Transmission; Transfection | 2018 |
Structural basis for recognition of diverse antidepressants by the human serotonin transporter.
Topics: Antidepressive Agents; Binding Sites; Chemistry, Pharmaceutical; Crystallography, X-Ray; Fluvoxamine; Humans; Kinetics; Mutation; Paroxetine; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2018 |
Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Linkage Disequilibrium; Male; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide | 2019 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Least-Squares Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2020 |
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
Topics: Case-Control Studies; Citalopram; Cohort Studies; Death, Sudden, Cardiac; Dialysis Solutions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Potassium; Renal Dialysis; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2022 |
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2022 |
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.
Topics: Adult; Bayes Theorem; Cohort Studies; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Fluvoxamine; Hospitalization; Humans; Outpatients; Paroxetine | 2023 |
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Topics: Adverse Drug Reaction Reporting Systems; Bayes Theorem; Fluvoxamine; Humans; Paroxetine; Pharmacovigilance; Rhabdomyolysis; Selective Serotonin Reuptake Inhibitors; United States; United States Food and Drug Administration | 2023 |
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
Topics: Antidepressive Agents; Brain; Carrier Proteins; Cell Line; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Radioligand Assay; Serotonin Plasma Membrane Transport Proteins; Symporters; Synaptosomes | 1997 |